NCT06128967View on ClinicalTrials.gov

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

May 18, 2025

Conditions
Long COVID-19 SyndromeChronic Fatigue Syndrome
Interventions
DRUG

Fluvoxamine Maleate 100 MG

Fluvoxamine Maleate 100 mg each pills

DRUG

Placebo

Placebo talc pills of same shape, color, weight if compared with active comparator

DRUG

Metformin Extended Release Oral Tablet

Metformin Extended release oral tablets of 750 mg each pill

Trial Locations (6)

30150240

RECRUITING

CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte

35400000

NOT_YET_RECRUITING

Universidade Federal de Ouro Preto, Ouro Preto

35.460-000

NOT_YET_RECRUITING

City of Brumadinho, Brumadinho

Unknown

RECRUITING

Governador Valadares City Public Health Authority, Governador Valadares

RECRUITING

City of Ibirité Public Health Authority, Ibirité

NOT_YET_RECRUITING

Sociedade Padrao de Educacao Superior, Montes Claros

Sponsors

Lead Sponsor

Cardresearch
All Listed Sponsors
lead

Cardresearch

OTHER

NCT06128967 - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial | Biotech Hunter | Biotech Hunter